You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameValdecoxib
Accession NumberDB00580  (APRD00183, DB07576)
TypeSmall Molecule
GroupsInvestigational, Withdrawn
DescriptionValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BextraNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2919279Q3W
CAS number181695-72-7
WeightAverage: 314.359
Monoisotopic: 314.072513014
Chemical FormulaC16H14N2O3S
InChI KeyLNPDTQAFDNKSHK-UHFFFAOYSA-N
InChI
InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
IUPAC Name
4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide
SMILES
CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O
Pharmacology
IndicationFor the treatment of osteoarthritis and dysmenorrhoea
Structured Indications Not Available
PharmacodynamicsValdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Valdecoxib is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain. Unlike celecoxib, valdecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism.
Mechanism of actionBoth COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Valdecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, valdecoxib does not inhibit platelet aggregation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Related Articles
AbsorptionOral bioavailability is 83%.
Volume of distribution
  • 86 L
Protein binding98%
Metabolism

Hepatic (involves CYP3A4 and 2C9)

SubstrateEnzymesProduct
Valdecoxib
Valdecoxib N-glucuronideDetails
Valdecoxib
Not Available
Valdecoxib metabolite M2Details
Valdecoxib metabolite M2
Valdecoxib metabolite M2 glucuronideDetails
Valdecoxib metabolite M2
Not Available
Valdecoxib metabolite M7Details
Valdecoxib metabolite M7
Not Available
Valdecoxib metabolite M8Details
Valdecoxib metabolite M2
Not Available
Valdecoxib metabolite M5Details
Valdecoxib metabolite M5
Valdecoxib metabolite M5 glucuronideDetails
Valdecoxib
Valdecoxib metabolite M1Details
Valdecoxib metabolite M1
Valdecoxib metabolite M1 glucuronideDetails
Valdecoxib metabolite M1
Not Available
Valdecoxib metabolite M5Details
Valdecoxib metabolite M1
Not Available
Valdecoxib metabolite M4Details
Valdecoxib metabolite M1
Not Available
Valdecoxib metabolite M3Details
Valdecoxib metabolite M3
Valdecoxib metabolite M3 glucuronideDetails
Valdecoxib
Valdecoxib metabolite M9Details
Valdecoxib metabolite M9
Valdecoxib metabolite M3Details
Valdecoxib metabolite M9
Valdecoxib metabolite M9 glucuronideDetails
Route of eliminationValdecoxib is eliminated predominantly via hepatic metabolism with less than 5% of the dose excreted unchanged in the urine and feces. About 70% of the dose is excreted in the urine as metabolites, and about 20% as valdecoxib N-glucuronide.
Half life8-11 hours
Clearance
  • oral cl=6 L/h
  • 6 – 7 L/h [In patients undergoing hemodialysis]
  • 6 – 7 L/h [healthy elderly subjects]
ToxicitySymptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Valdecoxib Action PathwayDrug actionSMP00116
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 5-androstenedione.Experimental, Illicit
AbciximabValdecoxib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Valdecoxib can be decreased when combined with Abiraterone.Approved
AcebutololValdecoxib may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Valdecoxib.Approved
AcenocoumarolValdecoxib may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Valdecoxib.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Valdecoxib.Approved, Vet Approved
AclarubicinValdecoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Valdecoxib.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Alendronic acid.Approved
AliskirenValdecoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololValdecoxib may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Valdecoxib.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Amcinonide.Approved
AmikacinValdecoxib may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideValdecoxib may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Valdecoxib can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinValdecoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodValdecoxib may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Valdecoxib.Investigational
annamycinValdecoxib may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Valdecoxib.Approved
Antithrombin III humanValdecoxib may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Valdecoxib may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanValdecoxib may increase the anticoagulant activities of Apixaban.Approved
ApramycinValdecoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Valdecoxib.Approved, Investigational
AprepitantThe serum concentration of Valdecoxib can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinValdecoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinValdecoxib may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanValdecoxib may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololValdecoxib may decrease the antihypertensive activities of Arotinolol.Approved
AtazanavirThe metabolism of Valdecoxib can be decreased when combined with Atazanavir.Approved, Investigational
AtenololValdecoxib may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Valdecoxib can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Valdecoxib.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Valdecoxib.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Valdecoxib.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Valdecoxib.Approved, Investigational
BazedoxifeneValdecoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminValdecoxib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololValdecoxib may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Valdecoxib.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Valdecoxib.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Valdecoxib.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Valdecoxib.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Betamethasone.Approved, Vet Approved
BetaxololValdecoxib may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Valdecoxib.Investigational
BevantololValdecoxib may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Valdecoxib can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Valdecoxib.Approved, Investigational
BisoprololValdecoxib may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinValdecoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Valdecoxib can be decreased when combined with Boceprevir.Approved
BopindololValdecoxib may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Valdecoxib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Valdecoxib can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Valdecoxib.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Valdecoxib.Investigational
BucindololValdecoxib may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Budesonide.Approved
BufuralolValdecoxib may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideValdecoxib may decrease the diuretic activities of Bumetanide.Approved
BupranololValdecoxib may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Valdecoxib.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Valdecoxib.Experimental
CapecitabineThe metabolism of Valdecoxib can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Valdecoxib.Approved
CarbamazepineThe metabolism of Valdecoxib can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Valdecoxib.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Valdecoxib.Approved, Vet Approved, Withdrawn
CarteololValdecoxib may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolValdecoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Valdecoxib.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Valdecoxib.Approved, Investigational
CeliprololValdecoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Valdecoxib can be increased when it is combined with Ceritinib.Approved
CertoparinValdecoxib may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Valdecoxib.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Valdecoxib.Approved, Vet Approved
ChlorotrianiseneValdecoxib may increase the thrombogenic activities of Chlorotrianisene.Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Valdecoxib.Approved
CholecalciferolThe metabolism of Valdecoxib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Valdecoxib.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Valdecoxib.Approved
CinoxacinValdecoxib may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinValdecoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramCitalopram may increase the antiplatelet activities of Valdecoxib.Approved
Citric AcidValdecoxib may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Valdecoxib can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Valdecoxib can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Valdecoxib.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Valdecoxib.Vet Approved
ClotrimazoleThe metabolism of Valdecoxib can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Valdecoxib can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Valdecoxib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensValdecoxib may increase the thrombogenic activities of Conjugated Equine Estrogens.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Valdecoxib can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Valdecoxib.Investigational
CyclosporineValdecoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Valdecoxib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Valdecoxib.Investigational
Dabigatran etexilateValdecoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Valdecoxib can be decreased when it is combined with Dabrafenib.Approved
DalteparinValdecoxib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidValdecoxib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Valdecoxib.Investigational
DarunavirThe metabolism of Valdecoxib can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Valdecoxib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinValdecoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Valdecoxib can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Valdecoxib can be decreased when combined with Delavirdine.Approved
DesirudinValdecoxib may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Valdecoxib.Approved
DexamethasoneThe serum concentration of Valdecoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Valdecoxib.Approved
DextranValdecoxib may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Valdecoxib may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Valdecoxib may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Valdecoxib may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Valdecoxib.Approved, Vet Approved
DicoumarolValdecoxib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolValdecoxib may increase the thrombogenic activities of Dienestrol.Approved
DiethylstilbestrolValdecoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Valdecoxib.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Valdecoxib.Approved
DihydroergotamineThe metabolism of Valdecoxib can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinValdecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe metabolism of Valdecoxib can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Valdecoxib.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Valdecoxib.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Valdecoxib.Approved
DoxorubicinValdecoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Valdecoxib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Valdecoxib can be decreased when combined with Dronedarone.Approved
DrospirenoneValdecoxib may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Valdecoxib.Approved
DuloxetineDuloxetine may increase the antiplatelet activities of Valdecoxib.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Valdecoxib.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Valdecoxib.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Valdecoxib.Investigational
Edetic AcidValdecoxib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanValdecoxib may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Valdecoxib can be decreased when it is combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Valdecoxib.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Valdecoxib.Approved
EnoxacinValdecoxib may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinValdecoxib may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Valdecoxib can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Valdecoxib.Approved
EpirubicinValdecoxib may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneValdecoxib may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Valdecoxib.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Valdecoxib.Approved
EquileninThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Equilin.Approved
ErythromycinThe metabolism of Valdecoxib can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the antiplatelet activities of Valdecoxib.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Valdecoxib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololValdecoxib may decrease the antihypertensive activities of Esmolol.Approved
EstradiolValdecoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
EstriolValdecoxib may increase the thrombogenic activities of Estriol.Approved, Vet Approved
EstroneValdecoxib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Estrone sulfate.Approved
Etacrynic acidValdecoxib may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Valdecoxib.Approved, Investigational
Ethinyl EstradiolValdecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateValdecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Valdecoxib.Approved
EtoperidoneEtoperidone may increase the antiplatelet activities of Valdecoxib.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Valdecoxib can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Valdecoxib.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Valdecoxib.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Valdecoxib.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Valdecoxib.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Valdecoxib.Vet Approved
FleroxacinValdecoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Valdecoxib.Approved, Withdrawn
FloxuridineThe metabolism of Valdecoxib can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with fluasterone.Investigational
FluconazoleThe metabolism of Valdecoxib can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fludrocortisone.Approved
FluindioneValdecoxib may increase the anticoagulant activities of Fluindione.Investigational
FlumequineValdecoxib may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Valdecoxib.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Valdecoxib can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Valdecoxib.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Valdecoxib.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Valdecoxib.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Valdecoxib can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Valdecoxib.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Valdecoxib.Approved, Nutraceutical, Vet Approved
FondaparinuxValdecoxib may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumValdecoxib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Valdecoxib.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Valdecoxib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Valdecoxib can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Valdecoxib.Approved
FosphenytoinThe metabolism of Valdecoxib can be increased when combined with Fosphenytoin.Approved
FramycetinValdecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideValdecoxib may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Valdecoxib can be increased when it is combined with Fusidic Acid.Approved
GabexateValdecoxib may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinValdecoxib may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinValdecoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Valdecoxib.Approved, Withdrawn
GemfibrozilThe metabolism of Valdecoxib can be decreased when combined with Gemfibrozil.Approved
GemifloxacinValdecoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinValdecoxib may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinValdecoxib may increase the thrombogenic activities of Genistein.Investigational
GentamicinValdecoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AValdecoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinValdecoxib may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Valdecoxib is combined with HE3286.Investigational
HeparinValdecoxib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolValdecoxib may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Valdecoxib.Investigational
HirulogValdecoxib may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Valdecoxib.Investigational
HydralazineValdecoxib may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Valdecoxib.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Valdecoxib.Approved
Hygromycin BValdecoxib may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Valdecoxib.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Valdecoxib.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Valdecoxib.Approved
IdarubicinValdecoxib may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Valdecoxib can be increased when it is combined with Idelalisib.Approved
idraparinuxValdecoxib may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Valdecoxib.Approved, Investigational
ImatinibThe metabolism of Valdecoxib can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Valdecoxib.Investigational
IndalpineIndalpine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Valdecoxib.Approved
IndenololValdecoxib may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Valdecoxib can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Valdecoxib.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Valdecoxib.Withdrawn
INNO-206Valdecoxib may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Valdecoxib can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Valdecoxib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Valdecoxib.Withdrawn
IsradipineThe metabolism of Valdecoxib can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Valdecoxib can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Valdecoxib can be increased when it is combined with Ivacaftor.Approved
KanamycinValdecoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Valdecoxib.Experimental
KetoconazoleThe metabolism of Valdecoxib can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Valdecoxib.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Valdecoxib.Approved
LabetalolValdecoxib may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Valdecoxib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Valdecoxib.Approved, Investigational
LepirudinValdecoxib may increase the anticoagulant activities of Lepirudin.Approved
LevobunololValdecoxib may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinValdecoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Valdecoxib.Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Valdecoxib.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Valdecoxib.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Valdecoxib.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Valdecoxib.Approved
LomefloxacinValdecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved
LopinavirThe metabolism of Valdecoxib can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Valdecoxib.Approved
LosartanThe metabolism of Valdecoxib can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Valdecoxib can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Valdecoxib.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Valdecoxib.Approved, Investigational
LuliconazoleThe serum concentration of Valdecoxib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Valdecoxib can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Valdecoxib.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Valdecoxib.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Valdecoxib.Approved
ME-609The risk or severity of adverse effects can be increased when Valdecoxib is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Valdecoxib.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Valdecoxib.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Valdecoxib.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Valdecoxib.Approved
MestranolValdecoxib may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Valdecoxib.Withdrawn
MethallenestrilValdecoxib may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Valdecoxib.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Valdecoxib.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Methylprednisolone.Approved, Vet Approved
MetipranololValdecoxib may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Valdecoxib.Approved
MetoprololValdecoxib may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideValdecoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Valdecoxib can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Valdecoxib.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Valdecoxib.Approved
MitotaneThe serum concentration of Valdecoxib can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Valdecoxib.Investigational
ModafinilThe serum concentration of Valdecoxib can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Valdecoxib.Approved
MometasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Valdecoxib.Approved
MoxifloxacinValdecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Valdecoxib.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Valdecoxib.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Valdecoxib.Approved
NadololValdecoxib may decrease the antihypertensive activities of Nadolol.Approved
NadroparinValdecoxib may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Valdecoxib.Investigational
NafcillinThe serum concentration of Valdecoxib can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Valdecoxib.Approved
Nalidixic AcidValdecoxib may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Valdecoxib.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Valdecoxib is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Valdecoxib.Investigational
NeamineValdecoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Valdecoxib can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Valdecoxib can be decreased when combined with Nelfinavir.Approved
NemonoxacinValdecoxib may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinValdecoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Valdecoxib.Approved
NetilmicinValdecoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Valdecoxib can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Valdecoxib can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Valdecoxib can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Valdecoxib.Approved
NilotinibThe metabolism of Valdecoxib can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Valdecoxib.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Valdecoxib.Investigational
NorfloxacinValdecoxib may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinValdecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe metabolism of Valdecoxib can be decreased when combined with Olaparib.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Valdecoxib.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Valdecoxib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Valdecoxib.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Valdecoxib.Investigational
OmeprazoleThe metabolism of Valdecoxib can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Valdecoxib.Vet Approved
OsimertinibThe serum concentration of Valdecoxib can be increased when it is combined with Osimertinib.Approved
OtamixabanValdecoxib may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Valdecoxib.Approved
OxprenololValdecoxib may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Valdecoxib.Withdrawn
PalbociclibThe serum concentration of Valdecoxib can be increased when it is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Parecoxib.Approved
ParomomycinValdecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Valdecoxib.Approved, Investigational
PazufloxacinValdecoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinValdecoxib may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololValdecoxib may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Valdecoxib can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateValdecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Valdecoxib.Approved
PhenindioneValdecoxib may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Valdecoxib can be increased when combined with Phenobarbital.Approved
PhenprocoumonValdecoxib may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Valdecoxib.Approved, Vet Approved
PhenytoinThe metabolism of Valdecoxib can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Valdecoxib.Approved, Investigational
PindololValdecoxib may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinValdecoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideValdecoxib may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Valdecoxib.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Valdecoxib.Approved, Investigational
PlicamycinValdecoxib may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
Polyestradiol phosphateValdecoxib may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Valdecoxib.Approved
PosaconazoleThe metabolism of Valdecoxib can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololValdecoxib may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Valdecoxib.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Valdecoxib can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Valdecoxib can be increased when it is combined with Probenecid.Approved
PromestrieneValdecoxib may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Valdecoxib.Approved
PropranololValdecoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Valdecoxib.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Valdecoxib.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Valdecoxib.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Valdecoxib.Vet Approved
Protein CValdecoxib may increase the anticoagulant activities of Protein C.Approved
Protein S humanValdecoxib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeValdecoxib may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinValdecoxib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Valdecoxib.Investigational
PuromycinValdecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Valdecoxib can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Valdecoxib.Approved, Investigational
QuinestrolValdecoxib may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Valdecoxib.Approved
QuinineThe metabolism of Valdecoxib can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Valdecoxib.Approved
RanolazineThe metabolism of Valdecoxib can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Valdecoxib.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Valdecoxib.Experimental, Investigational
ReviparinValdecoxib may increase the anticoagulant activities of Reviparin.Approved
RibostamycinValdecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Valdecoxib can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Valdecoxib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Valdecoxib can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Valdecoxib can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanValdecoxib may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Valdecoxib.Investigational, Withdrawn
RosoxacinValdecoxib may increase the neuroexcitatory activities of Rosoxacin.Approved
S EquolValdecoxib may increase the thrombogenic activities of S Equol.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Valdecoxib.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Valdecoxib.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Valdecoxib.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Valdecoxib.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Valdecoxib.Experimental
SaquinavirThe metabolism of Valdecoxib can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Valdecoxib.Investigational
SecobarbitalThe metabolism of Valdecoxib can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolValdecoxib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Valdecoxib.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Valdecoxib.Approved
SildenafilThe metabolism of Valdecoxib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Valdecoxib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Valdecoxib can be increased when it is combined with Simeprevir.Approved
SisomicinValdecoxib may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Valdecoxib can be decreased when combined with Sorafenib.Approved, Investigational
SotalolValdecoxib may decrease the antihypertensive activities of Sotalol.Approved
SP1049CValdecoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinValdecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinValdecoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Valdecoxib.Approved
SpironolactoneValdecoxib may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Valdecoxib.Investigational
St. John's WortThe serum concentration of Valdecoxib can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Valdecoxib can be increased when it is combined with Stiripentol.Approved
StreptomycinValdecoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinValdecoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Valdecoxib can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Valdecoxib can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Valdecoxib.Approved
SulfisoxazoleThe metabolism of Valdecoxib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Valdecoxib.Approved
SulodexideValdecoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Valdecoxib.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Valdecoxib.Approved, Withdrawn
Synthetic Conjugated Estrogens, AValdecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BValdecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusValdecoxib may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Valdecoxib.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Valdecoxib.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Valdecoxib.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Technetium Tc-99m Medronate.Approved
TelaprevirThe metabolism of Valdecoxib can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Valdecoxib can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Valdecoxib.Approved, Investigational
TemafloxacinValdecoxib may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Valdecoxib.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Valdecoxib.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Valdecoxib.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Valdecoxib.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Valdecoxib.Approved
TiboloneValdecoxib may increase the thrombogenic activities of Tibolone.Approved
TicagrelorThe metabolism of Valdecoxib can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Valdecoxib can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tiludronate.Approved, Vet Approved
TimololValdecoxib may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Valdecoxib.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tixocortol.Approved
TobramycinValdecoxib may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Valdecoxib can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Valdecoxib can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Valdecoxib.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Valdecoxib.Approved
TorasemideValdecoxib may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Valdecoxib.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Valdecoxib.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Valdecoxib.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Valdecoxib.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Triamcinolone.Approved, Vet Approved
TriamtereneValdecoxib may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Valdecoxib.Approved, Vet Approved
TrimethoprimThe metabolism of Valdecoxib can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Valdecoxib.Approved
TrovafloxacinValdecoxib may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Valdecoxib.Approved
Valproic AcidThe metabolism of Valdecoxib can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinValdecoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Valdecoxib can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Valdecoxib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Valdecoxib.Approved
VerapamilThe metabolism of Valdecoxib can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Valdecoxib can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinValdecoxib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranValdecoxib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Valdecoxib may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Valdecoxib can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Valdecoxib.Approved
ZeranolValdecoxib may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Valdecoxib.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Valdecoxib.Withdrawn
ZiprasidoneThe metabolism of Valdecoxib can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Valdecoxib.Withdrawn
ZorubicinValdecoxib may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Eswaraiah Sajja, Anumula Reddy, Aalla Sampath, Gilla Goverdhan, “Process for preparing crystalline form A of valdecoxib.” U.S. Patent US20050272787, issued December 08, 2005.

US20050272787
General ReferencesNot Available
External Links
ATC CodesM01AH03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (82.8 KB)
MSDSDownload (70.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9386
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.8864
P-glycoprotein inhibitor INon-inhibitor0.8772
P-glycoprotein inhibitor IINon-inhibitor0.9157
Renal organic cation transporterNon-inhibitor0.8576
CYP450 2C9 substrateNon-substrate0.7356
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6501
CYP450 1A2 substrateNon-inhibitor0.5759
CYP450 2C9 inhibitorInhibitor0.5385
CYP450 2D6 inhibitorNon-inhibitor0.8875
CYP450 2C19 inhibitorInhibitor0.5958
CYP450 3A4 inhibitorNon-inhibitor0.8652
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7649
Ames testNon AMES toxic0.8277
CarcinogenicityNon-carcinogens0.7399
BiodegradationNot ready biodegradable0.9948
Rat acute toxicity2.0680 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9708
hERG inhibition (predictor II)Non-inhibitor0.8652
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Gd searle llc
Packagers
Dosage formsNot Available
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2212836 No2003-08-122016-02-12Canada
US5633272 No1995-02-132015-02-13Us
US7135489 No1997-08-122017-08-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0348 mg/mLALOGPS
logP3.32ALOGPS
logP2.82ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)10.06ChemAxon
pKa (Strongest Basic)0.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.19 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity84.71 m3·mol-1ChemAxon
Polarizability31.76 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Oxazole
  • Isoxazole
  • Azole
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K: 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem. 2000 Mar 9;43(5):775-7. [PubMed:10715145 ]
  2. Jain KK: Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Investig Drugs. 2000 Nov;9(11):2717-23. [PubMed:11060833 ]
  3. Yuan JJ, Yang DC, Zhang JY, Bible R Jr, Karim A, Findlay JW: Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab Dispos. 2002 Sep;30(9):1013-21. [PubMed:12167567 ]
  4. Tacconelli S, Capone ML, Sciulli MG, Ricciotti E, Patrignani P: The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin. 2002;18(8):503-11. [PubMed:12564662 ]
  5. Hood WF, Gierse JK, Isakson PC, Kiefer JR, Kurumbail RG, Seibert K, Monahan JB: Characterization of celecoxib and valdecoxib binding to cyclooxygenase. Mol Pharmacol. 2003 Apr;63(4):870-7. [PubMed:12644588 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K: Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19. [PubMed:15494548 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23